FibroBiologics Announces 1H Results: Net Loss of $9.6mln, Cash at $8.8mln

FibroBiologics reported a net loss of approximately $9.6 million in 1H 2025, compared to a net loss of approximately $7.6 million in 1H 2024. Cash and cash equivalents totaled approximately $8.8 million at June 30, 2025.

Houston, TX - July 2, 2025 - FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, released its second quarter 2025 financial results and provided a corporate update. The company reported a net loss of approximately $9.6 million for the six months ended June 30, 2025, compared to a net loss of $7.6 million for the same period in 2024. Cash and cash equivalents totaled approximately $8.8 million as of June 30, 2025.

FibroBiologics secured the third $5 million tranche of a $25 million total financing, with proceeds used to advance research and development efforts and support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs). The company appointed Jason D. Davis, CPA, as Chief Financial Officer, who brings over 25 years of experience in building and leading organizations.

The company presented pre-clinical evidence at the Society for Investigative Dermatology Annual Meeting supporting the potential of fibroblast spheroids to reduce psoriasis severity. FibroBiologics highlighted the potential of fibroblast-based therapies for chronic disease treatments at the BIO International Convention 2025. The company confirmed the use of the CYWC628 master cell bank for the manufacturing of CybroCell™, FibroBiologics’ investigational intradiscal administered allogeneic fibroblast cell-based therapy in development for degenerative disc disease.

Key upcoming milestones include initiating a Phase 1/2 clinical trial in Australia evaluating fibroblast-based spheroids product candidate, CYWC628, in DFU patients in the first quarter of 2026. The company also plans to complete pre-clinical IND-enabling studies for the treatment of psoriasis with CYPS317 by the end of 2025.

Research and development expenses were approximately $3.8 million for the six months ended June 30, 2025, compared to approximately $1.9 million for the same period in 2024. The increase was primarily due to increased chemistry, manufacturing and control costs, increased CRO costs, increased personnel related expenses, and increased research materials and supplies expenses.

General and administrative expenses were approximately $5.2 million for the six months ended June 30, 2025, compared to approximately $4.7 million for the same period in 2024. The increase was primarily due to increased expenses for added personnel in 2025, increased professional fees, increased travel expenses, and decreased Direct Listing related expenses.

FibroBiologics continues to advance its fibroblast-based therapeutic pipeline with notable pre-clinical progress, though at the cost of deepening financial losses. The company secured an additional $5 million tranche from its $25 million financing arrangement, providing essential capital for near-term operations. With approximately $8.8 million in cash as of June 30, and considering the $9.6 million net loss for the first half of 2025, the runway appears sufficient to reach their upcoming Q1 2026 clinical milestone for diabetic foot ulcers (DFUs).

References:
[1] https://www.nasdaq.com/press-release/fibrobiologics-reports-second-quarter-2025-financial-results-and-provides-corporate
[2] https://www.stocktitan.net/news/FBLG/fibro-biologics-reports-second-quarter-2025-financial-results-and-soo7fvmg1ws8.html